Pre-filtered biogenic molecule database for docking

Problem Context

Researchers need to identify natural substrates for uncharacterized enzymes like P450s. They use docking screening, but require a specialized database of biogenic molecules (max 30,000) with 3D structures. Existing databases either lack biogenic filtering or don't provide 3D formats, forcing manual curation that wastes time and computational resources.

Pain Points

Current solutions like ZINC don’t let users filter for biogenic molecules, and 3DMET is down. Researchers must manually curate datasets, which is time-consuming and error-prone. Without the right database, their docking screening fails, delaying research progress. The lack of 3D structures in most databases forces extra conversion steps, adding more work.

Impact

Wasted computational time costs labs thousands per failed screening. Delayed research means missed grant deadlines or slower drug discovery. Frustration leads to inefficient workarounds, like using incomplete datasets or abandoning projects. For pharma labs, this directly impacts R&D timelines and budgets.

Urgency

This is a blocking issue—without the right database, researchers can’t proceed with docking. Every day spent searching for or curating a database is a day not spent on actual research. Labs with tight deadlines (e.g., grant-funded projects) can’t afford delays, making this a high-priority problem.

Target Audience

Computational biochemists, drug discovery researchers, and academic labs working on enzyme characterization. Pharma companies running high-throughput screening also face this issue. Anyone using docking software (e.g., AutoDock, GROMACS) for substrate identification needs this.

Solution Approach

A specialized database of pre-filtered biogenic molecules (max 30,000) with guaranteed 3D structures, optimized for docking screening. Users pay a monthly fee for API access or annual for bulk downloads. The database is curated from high-quality sources, ensuring relevance and reducing manual work.

Key Features

1. Guaranteed 3D structures: All molecules provided in .sdf format, ready for docking.
2. API for integration: Direct access to the database from docking software (e.g., AutoDock).
3. Monthly updates: New molecules added based on research trends.

User Experience

Researchers sign up, get API credentials, and integrate the database into their docking workflow. No manual curation needed—the database is ready to use. For bulk users, they download the .sdf files and import them directly. Updates are automatic, so the database stays current without extra effort.

Differentiation

Unlike ZINC or 3DMET, this focuses only on biogenic molecules with 3D structures. No filtering needed—users get exactly what they require for docking. The API integration saves hours of setup time. Competitors either lack biogenic filtering or are unreliable (e.g., 3DMET downtime).

Scalability

Start with P450 enzymes, then expand to other enzyme classes (e.g., CYP2D6) as paid tiers. Add more molecules over time to keep the database growing. Enterprise plans for pharma labs with higher usage limits. Upsell analytics (e.g., substrate binding predictions) later.

Expected Impact

Researchers save 10+ hours per screening project. Labs avoid wasted computational costs. Faster docking means quicker substrate identification, accelerating drug discovery. Pharma companies reduce R&D timelines, improving ROI on screening efforts.